Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis

被引:50
作者
Janssen-Heijnen, M. L. G. [1 ,2 ]
van Erning, F. N. [3 ]
De Ruysscher, D. K. [4 ]
Coebergh, J. W. W. [3 ,5 ]
Groen, H. J. M. [6 ]
机构
[1] VieCuri Med Ctr, Dept Clin Epidemiol, NL-5900 BX Venlo, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Epidemiol, GROW Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands
[3] Comprehens Canc Ctr Netherlands, Dept Res, Eindhoven, Netherlands
[4] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium
[5] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands
关键词
causes of death; conditional survival; excess mortality; long-term; non-small cell lung cancer; CONDITIONAL SURVIVAL; COMORBIDITY; MORTALITY; SMOKING; PREVALENCE; PROGNOSIS; AGE;
D O I
10.1093/annonc/mdv061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Many patients with non-small cell lung cancer (NSCLC) die within the first few years of diagnosis, and considerable excess mortality remains even after 5 years. We investigated the death rate and the distribution of causes of death for NSCLC patients by age and stage at diagnosis during long-term follow-up. Patients and methods: All 72 021 patients aged 45-89 years diagnosed with stage I-III NSCLC between 1989 and 2008 in the Netherlands and who died up till 2011 were derived from the Netherlands Cancer Registry and linked with the database of Statistics Netherlands for underlying causes of death. Mortality ratios and proportional distribution of causes of death were calculated during 5 time periods after diagnosis of NSCLC (up to 15 years). Results: Median follow-up was 9.6 years (range: 0-23 years). Lung cancer was the predominant cause of death in the first 6 years after diagnosis (being 80%-85% and similar to 90% up to 3 years for localized and locally advanced disease, respectively, and similar to 60%-75% and similar to 75%-85% during years 4-6 for both stage groups, respectively). Thereafter, lung cancer as cause of death proportionally decreased with time since diagnosis, but remained over 30%. Hence, cardiovascular diseases and chronic obstructive pulmonary diseases (COPD) became more important causes of death, especially for patients aged >60 years at diagnosis (up to 34% for cardiovascular diseases and up to 19% for COPD). Conclusions: With time, the relative contribution of cardiovascular and COPD causes of death increased, although the absolute contribution of lung cancer remained high in non-metastatic NSCLC. Therefore, managing morbidity of these diseases remains relevant.
引用
收藏
页码:902 / 907
页数:6
相关论文
共 38 条
[1]   Computed Tomography Screening for Lung Cancer: Has It Finally Arrived? Implications of the National Lung Screening Trial [J].
Aberle, Denise R. ;
Abtin, Fereidoun ;
Brown, Kathleen .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :1002-1008
[2]   Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening [J].
Aberle, Denise R. ;
Adams, Amanda M. ;
Berg, Christine D. ;
Black, William C. ;
Clapp, Jonathan D. ;
Fagerstrom, Richard M. ;
Gareen, Ilana F. ;
Gatsonis, Constantine ;
Marcus, Pamela M. ;
Sicks, JoRean D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) :395-409
[3]  
[Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590
[4]   When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects [J].
Baade, Peter D. ;
Youlden, Danny R. ;
Chambers, Suzanne K. .
MEDICAL JOURNAL OF AUSTRALIA, 2011, 194 (02) :73-77
[5]   Conditional Relative Survival of Cancer Patients and Conditional Probability of Death [J].
Bouvier, Anne-Marie ;
Remontet, Laurent ;
Hedelin, Guy ;
Launoy, Guy ;
Jooste, Valerie ;
Grosclaude, Pascale ;
Belot, Aurelien ;
Lacour, Brigitte ;
Esteve, Jacques ;
Bossard, Nadine ;
Faivre, Jean .
CANCER, 2009, 115 (19) :4616-4624
[6]   Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10 [J].
Butts, Charles A. ;
Ding, Keyue ;
Seymour, Lesley ;
Twumasi-Ankrah, Philip ;
Graham, Barbara ;
Gandara, David ;
Johnson, David H. ;
Kesler, Kenneth A. ;
Green, Mark ;
Vincent, Mark ;
Cormier, Yvon ;
Goss, Glenwood ;
Findlay, Brian ;
Johnston, Michael ;
Tsao, Ming-Sound ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :29-34
[7]   Risks of second primary cancer among patients with major histological types of lung cancers in both men and women [J].
Chuang, S-C ;
Scelo, G. ;
Lee, Y-C A. ;
Friis, S. ;
Pukkala, E. ;
Brewster, D. H. ;
Hemminki, K. ;
Tracey, E. ;
Weiderpass, E. ;
Tamaro, S. ;
Pompe-Kirn, V. ;
Kliewer, E. V. ;
Chia, K-S ;
Tonita, J. M. ;
Martos, C. ;
Jonasson, J. G. ;
Boffetta, P. ;
Brennan, P. ;
Hashibe, M. .
BRITISH JOURNAL OF CANCER, 2010, 102 (07) :1190-1195
[8]   Early and long-term results of pulmonary resection for non-small-cell lung cancer in patients over 75 years of age: a multi-institutional study [J].
Dell'Amore, Andrea ;
Monteverde, Marco ;
Martucci, Nicola ;
Sanna, Stefano ;
Caroli, Guido ;
Stella, Franco ;
Dell'Amore, Davide ;
Rocco, Gaetano .
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2013, 16 (03) :250-256
[9]   MORTALITY IN RELATION TO SMOKING - 40 YEARS OBSERVATIONS ON MALE BRITISH DOCTORS [J].
DOLL, R ;
PETO, R ;
WHEATLEY, K ;
GRAY, R ;
SUTHERLAND, I .
BRITISH MEDICAL JOURNAL, 1994, 309 (6959) :901-911
[10]   Second primary tumors involving non-small cell lung cancer - Prevalence and its influence on survival [J].
Duchateau, CSJ ;
Stokkel, MPM .
CHEST, 2005, 127 (04) :1152-1158